v3.25.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Current assets:    
Cash and cash equivalents $ 90,265 $ 101,654
Short-term restricted cash 1,410 1,330
Investment in equity securities 2,382 3,529
Trade and other receivables, net 5,544 1,839
Short-term royalty and commercial payment receivables under the EIR method 12,240 14,763
Short-term royalty and commercial payment receivables under the cost recovery method 413 413
Prepaid expenses and other current assets 971 2,076
Total current assets 113,225 125,604
Long-term restricted cash 3,352 3,432
Property and equipment, net 29 32
Operating lease right-of-use assets 304 319
Long-term royalty and commercial payment receivables under EIR method 4,857 4,970
Long-term royalty and commercial payment receivables under the cost recovery method 59,916 55,936
Exarafenib milestone asset (Note 4) 3,307 3,214
Investment in warrants 605  
Intangible assets, net 25,365 25,909
Other assets - long term 1,790 1,861
Total assets 212,750 221,277
Current liabilities:    
Accounts payable 2,319 1,053
Accrued and other liabilities 1,221 5,752
Contingent consideration under RPAs, AAAs, and CPPAs   3,000
Operating lease liabilities 459 446
Unearned revenue recognized under units-of-revenue method 1,370 1,361
Preferred stock dividend accrual 1,368 1,368
Current portion of long-term debt 13,697 11,394
Total current liabilities 20,434 24,374
Unearned revenue recognized under units-of-revenue method - long-term 4,084 4,410
Exarafenib milestone contingent consideration (Note 4) 3,307 3,214
Long-term operating lease liabilities 362 483
Long-term debt 99,934 106,875
Total liabilities 128,121 139,356
Commitments and Contingencies (Note 10)
Stockholders' equity:    
Common stock, $0.0075 par value, 277,333,332 shares authorized, 11,952,889 and 11,952,377 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively 90 90
Additional paid-in capital 1,319,607 1,318,766
Accumulated other comprehensive income 118 73
Accumulated deficit (1,235,235) (1,237,057)
Total stockholders' equity 84,629 81,921
Total liabilities and stockholders' equity 212,750 221,277
8.625% Series A Cumulative, Perpetual Preferred Stock    
Stockholders' equity:    
Preferred Stock 49 49
8.375% Series B Cumulative, Perpetual Preferred Stock    
Stockholders' equity:    
Preferred Stock
Convertible preferred stock    
Stockholders' equity:    
Preferred Stock

Source